LICENSE & SUPPLY AGREEMENTLicense & Supply Agreement • December 27th, 2022 • Priveterra Acquisition Corp. • Blank checks
THIS LICENSE AND SUPPLY AGREEMENT (hereinafter this “Agreement”) is entered into this 20th day of December, 2019 (the “Effective Date”), by and between Daewoong Pharmaceutical Co., Ltd, a corporation organized and existing under the laws of the Republic of Korea, having its main office at Bongeunsaro 114-gil 12, Gangnam-gu, Seoul 06170 (hereinafter “DAEWOONG”); and AEON Biopharma, Inc., a corporation organized and existing under the laws of Delaware, United States, having its main office at 4040 MacArthur Blvd, Newport Beach, CA, USA 92660 (hereinafter “AEON”).
CONFIDENTIAL LICENSE & SUPPLY AGREEMENT dated as of August 9, 2004 between PRONOVA BIOCARE A.S. Postboks 420, Vollsveien 6, NO-1327 Lysaker, Norway (hereinafter “PRONOVA”) and RELIANT PHARMACEUTICALS, INC. (hereinafter “RELIANT”) collectively referred...License & Supply Agreement • September 14th, 2007 • Reliant Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
WHEREAS, PRONOVA owns and/or controls certain intellectual property rights and know-how with respect to a pharmaceutical product known as Omacor® and has the manufacturing skills to produce Omacor®;
FIRST AMENDMENTLicense & Supply Agreement • January 9th, 2018 • Evolus, Inc. • Pharmaceutical preparations
This FIRST AMENDMENT (“First Amendment”) is effective as of February 26, 2014 (“First Amendment Effective Date”), by and between Daewoong Pharmaceutical Co., Ltd. (“DAEWOONG”) and Evolus Inc. (“EVOLUS”), and amends that certain License & Supply Agreement between the Parties dated September 30, 2013 (the “Original Agreement”).
LICENSE & SUPPLY AGREEMENTLicense & Supply Agreement • January 9th, 2018 • Evolus, Inc. • Pharmaceutical preparations
THIS LICENSE AND SUPPLY AGREEMENT (hereinafter this “Agreement”) is entered into this 30th day of September, 2013 (the “Effective Date”), by and between Daewoong Pharmaceutical Co., Ltd, a corporation organized and existing under the laws of the Republic of Korea, having its main office at 163-3, Samsung-Dong, Kangnam-Gu, Seoul, 135-715, Korea (hereinafter “DAEWOONG”); and Evolus Inc., a corporation organized and existing under the laws of Delaware, United States, having its main office at 1270 Via Brigitte, Santa Barbara, CA, USA 93111 (hereinafter “EVOLUS”).
SECOND AMENDMENTLicense & Supply Agreement • January 9th, 2018 • Evolus, Inc. • Pharmaceutical preparations
This SECOND AMENDMENT (“Second Amendment”) is effective as of July 15, 2014 (“Second Amendment Effective Date”), by and between Daewoong Pharmaceutical Co., Ltd. (“DAEWOONG”) and Evolus Inc. (“EVOLUS”), and amends that certain License & Supply Agreement between the Parties dated September 30, 2013, as amended by that certain First Amendment dated on February 26, 2014 (the “Original Agreement”).
CONFIDENTIAL LICENSE & SUPPLY AGREEMENT dated as of August 9, 2004 between PRONOVA BIOCARE A.S. Postboks 420, Vollsveien 6, NO-1327 Lysaker, Norway (hereinafter “PRONOVA”) and RELIANT PHARMACEUTICALS, INC. (hereinafter “RELIANT”) collectively referred...License & Supply Agreement • October 26th, 2007 • Reliant Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
WHEREAS, PRONOVA owns and/or controls certain intellectual property rights and know-how with respect to a pharmaceutical product known as Omacor® and has the manufacturing skills to produce Omacor®;
LICENSE & SUPPLY AGREEMENTLicense & Supply Agreement • April 4th, 2007 • Forbes Medi Tech Inc • Pharmaceutical preparations • California
THIS LICENSE & SUPPLY AGREEMENT (“Agreement”) is made as of January 1, 2006 (hereinafter the "Effective Date"), by and between FORBES MEDI-TECH, INC., a corporation existing and organized under the Canada Business Corporation Act, having its headquarters at 750 West Pender Street, Suite 200, Vancouver, B.C. V6C 2T8 (hereinafter referred to as “FORBES”), and PHARMAVITE LLC, a limited liability company existing and organized under the laws of the State of California, having its headquarters at 8510 Balboa Boulevard, Suite 300, Northridge, California 91325 (hereinafter referred to as “PHARMAVITE”).
THIRD AMENDMENTLicense & Supply Agreement • May 12th, 2021 • Evolus, Inc. • Pharmaceutical preparations
This Third Amendment (“Third Amendment”) is entered into on March 23, 2021 (“Third Amendment Effective Date”) by and between Daewoong Pharmaceutical Co., Ltd. (“DAEWOONG”) and Evolus Inc. (“EVOLUS”) and amends that certain License & Supply Agreement between the Parties dated September 30, 2013, as amended by that certain First Amendment dated February 26, 2014 and that certain Second Amendment dated July 15, 2014 (collectively, the “Original Agreement”).
5TH AMENDMENTLicense & Supply Agreement • August 2nd, 2023 • Evolus, Inc. • Pharmaceutical preparations
This 5TH AMENDMENT (“5th Amendment”) is made and entered into on April 20th, 2023 (“5th Amendment Effective Date”) by and between Daewoong Pharmaceutical Co., Ltd. (“DAEWOONG”) and Evolus, Inc. EVOLUS and
LICENSE & SUPPLY AGREEMENTLicense & Supply Agreement • March 8th, 2023 • Evolus, Inc. • Pharmaceutical preparations
THIS LICENSE AND SUPPLY AGREEMENT (hereinafter this “Agreement”) is entered into this 30th day of September, 2013 (the “Effective Date”), by and between Daewoong Pharmaceutical Co., Ltd, a corporation organized and existing under the laws of the Republic of Korea, having its main office at 163-3, Samsung-Dong, Kangnam-Gu, Seoul, 135-715, Korea (hereinafter “DAEWOONG”); and Evolus Inc., a corporation organized and existing under the laws of Delaware, United States, having its main office at 1270 Via Brigitte, Santa Barbara, CA, USA 93111 (hereinafter “EVOLUS”).
ContractLicense & Supply Agreement • May 5th, 2020
EX-10.4 11 exhibit104s-1.htm EXHIBIT 10.4 Exhibit 10.4 FIRST AMENDMENT This FIRST AMENDMENT (“First Amendment”) is effective as of February 26, 2014 (“First Amendment Effective Date”), by and between Daewoong Pharmaceutical Co., Ltd. (“DAEWOONG”) and Evolus Inc. (“EVOLUS”), and amends that certain License & Supply Agreement between the Parties dated September 30, 2013 (the “Original Agreement”). The Parties, for their mutual benefit, now wish to amend the Original Agreement. Capitalized terms herein used which are not herein defined shall have the respective meanings ascribed to them in the Original Agreement. All references to the term “Agreement” in the Original Agreement shall be deemed to include all of the terms and conditions of this First Amendment. NOW, THEREFORE, in consideration of the mutual promises hereinafter set forth, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties hereto agree as follows: 1.AMENDME
August 23, 2004License & Supply Agreement • August 10th, 2007 • Reliant Pharmaceuticals, Inc. • Pharmaceutical preparations
We refer to that certain License & Supply Agreement, dated as of August 9, 2004 (the “Agreement”), between Pronova Biocare a.s. (“Pronova”) and Reliant Pharmaceuticals, Inc. (“Reliant”).
RECITALSLicense & Supply Agreement • March 30th, 2000 • Staar Surgical Company • Ophthalmic goods • California
FOURTH AMENDMENTLicense & Supply Agreement • December 13th, 2022 • Evolus, Inc. • Pharmaceutical preparations
This FOURTH AMENDMENT (“Fourth Amendment”) is entered into on December 12, 2022 (“Fourth Amendment Effective Date”) by and between Daewoong Pharmaceutical Co., Ltd. (“DAEWOONG”) and Evolus Inc. (“EVOLUS”) and amends that certain License & Supply Agreement between the Parties dated September 30, 2013, as amended by that certain First Amendment dated February 26, 2014, that certain Second Amendment dated July 15, 2014 and that certain Third Amendment dated March 23, 2021 (collectively, the “Original Agreement”).
FIRST AMENDMENTLicense & Supply Agreement • March 7th, 2024 • Evolus, Inc. • Pharmaceutical preparations
This FIRST AMENDMENT (“First Amendment ”) is effective as of February 26, 2014 (“First Amendment Effective Date ”), by and between Daewoong Pharmaceutical Co., Ltd. (“DAEWOONG ”) and Evolus Inc. (“EVOLUS ”), and amends that certain License & Supply Agreement between the Parties dated September 30, 2013 (the “Original Agreement ”).
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT BOTH (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED TEXT OMITTED FROM THIS EXHIBIT IS MARKED WITH [***] License & Supply Agreement KYE...License & Supply Agreement • August 20th, 2020 • Catalyst Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
THIS LICENSE & SUPPLY AGREEMENT is made as of 14th August 2020 (“Effective Date”) by and between KYE Pharmaceuticals Inc., 2233 Argentia Road Suite 302 and 302A, Mississauga Ontario Canada L5N 2X7 Canada, a corporation incorporated under the laws of Ontario, Canada (“KYE”) and Catalyst Pharmaceuticals, Inc., 355 Alhambra Circle, Suite 1250 Coral Gables, Florida (“CATALYST”) a corporation incorporated under the laws of the state of Florida, United States of America.
Reliant Pharmaceuticals, Inc. 110 Allen Road Liberty Corner, NJ 07938 908-580-1200 Fax: 908-542-9405License & Supply Agreement • May 20th, 2005 • Reliant Pharmaceuticals, Inc.
We refer to that certain License & Supply Agreement, dated as of August 9, 2004 (the “Agreement”), between Pronova Biocare a.s. (“Pronova”) and Reliant Pharmaceuticals, Inc. (“Reliant”).
SIXTH AMENDMENTLicense & Supply Agreement • May 7th, 2024 • Evolus, Inc. • Pharmaceutical preparations
This SIXTH AMENDMENT (“Sixth Amendment”) is made and entered into on February __, 2024 (“Sixth Amendment Effective Date”) by and between Daewoong Pharmaceutical Co., Ltd. (“DAEWOONG”) and Evolus, Inc. (“EVOLUS”) and amends that certain License & Supply Agreement between the Parties dated September 30, 2013, as amended by that certain First Amendment dated February 26, 2014, that certain Second Amendment dated July 15, 2014, that certain Third Amendment dated March 23, 2021, that certain fourth Amendment dated December 12, 2022, and that certain 5th Amendment dated April 20, 2023 (collectively, the “Original Agreement”).
SECOND AMENDMENTLicense & Supply Agreement • March 7th, 2024 • Evolus, Inc. • Pharmaceutical preparations
This SECOND AMENDMENT (“Second Amendment ”) is effective as of July 15, 2014 (“Second Amendment Effective Date ”), by and between Daewoong Pharmaceutical Co., Ltd. (“DAEWOONG ”) and Evolus Inc. (“EVOLUS ”), and amends that certain License & Supply Agreement between the Parties dated September 30, 2013, as amended by that certain First Amendment dated on February 26, 2014 (the “Original Agreement ”).
